Introduction
Obstetric venous thromboembolism (VTE) is a leading cause of maternal morbidity and mortality. The World Health Organization implicated embolism in over 14% of maternal deaths in the developed world (1) . It is the leading cause of direct maternal death in the UK and Ireland, and is the second leading cause of direct maternal death in the Nordic countries (2, 3) . According to the Confidential Enquiry into Maternal Deaths in the UK and Ireland, more than four-fifths of those women who died from VTE between 2011 and 2013 had recognizable risk factors for thromboembolism (4) . In many cases, these risk factors were either not recognized or not acted upon. This highlights the critical need to improve recognition of women who are at risk of VTE, in order to deliver riskappropriate thromboprophylaxis and effectively prevent pregnancy-associated VTE.
International guidelines recommend venous thromboembolism risk assessment (VTERA) in all pregnant and postpartum women, and the initiation of thromboprophylaxis in those identified to be at increased risk of VTE (5) (6) (7) (8) (9) (10) (11) . Despite the potentially devastating consequences of pregnancy-associated VTE and established international recommendations, compliance with VTERA in obstetric settings is reported to be poor (12) . There are several underlying reasons for this. First, until very recently (13) , no validated tools existed to determine absolute postpartum VTE risk accurately. Secondly, the optimal threshold for initiating pharmacological thromboprophylaxis and recommended duration is unclear. A lack of consensus among international guidelines (5) (6) (7) (8) (9) (10) (11) reflects the paucity of high-quality evidence from randomized trials to guide recommendations; an issue which was highlighted by a recent Cochrane review (14) . Finally, and importantly, implementing a systematic means of assessing each woman's individual risk of VTE is very challenging in busy, high-throughput environments such as the labor or postnatal wards. There is a common need to develop robust VTERA mechanisms in order to reduce VTErelated morbidity and mortality.
In our institution, care providers reported that currently available paper-based risk assessment tools were not suitable for use in a high-throughput environment and were sometimes difficult to interpret. Given the large numbers of women that require risk assessment, we hypothesized that an electronic VTERA tool based on calculation of a final "score" would allow for easier and faster VTERA.
The concept of using weighted risk factors to obtain a final "score" to guide thromboprophylaxis strategies was reported over 25 years ago in general surgical patients (15) . In an obstetric setting, a score-based model for individualized assessment of VTE risk was reported in Sweden in the early 2000s (16) , with several other scorebased VTERA tools subsequently reported in the literature (8, (17) (18) (19) (20) . Most recently, a validated risk prediction model to estimate the absolute risk of postpartum VTE was reported (13) . However, widespread implementation of these risk assessment tools was not reported. Furthermore, evidence to support the use of electronic tools for VTERA is primarily limited to non-obstetric settings (21, 22) . The suitability and feasibility of widespread implementation of an electronic, score-based VTERA tool in a busy obstetric environment remain undetermined.
We aimed to develop, pilot and implement a userfriendly electronic VTERA tool, Thrombocalc, to facilitate standardized VTERA in a high-throughput setting. As the risk of VTE per day is highest in the first 6 weeks after childbirth (23, 24) , we chose to prioritize the development of a postnatal VTERA tool. The principal outcome measure was compliance with this risk assessment tool. We did not assess clinical outcomes in this study phase.
Material and methods
The Rotunda Hospital is tertiary referral university teaching hospital in an urban setting. The Rotunda Hospital has delivered over 8000 mothers per year over the last 5 years. The pilot phase of this project began in September 2014 and data collection for this report continued until December 2015. The Thrombocalc Development Group was multidisciplinary and included input from obstetrics and gynecology, hematology, midwifery, nursing, pharmacy, anesthesia, hospital administration and information technology. Through multidisciplinary collaboration, a novel electronic risk assessment tool, Thrombocalc, was developed using EXCEL ™ (Microsoft Corp., Redmond, WA, USA).
The VTERA tool included maternal-, pregnancy-and
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delivery-associated clinical characteristics which are reported as risk factors for postpartum VTE in epidemiological studies and are considered in international guidelines (5, 6) . A score was assigned to each risk factor that was broadly weighted in line with published odds ratios and incidence rate ratios (23, (25) (26) (27) (28) . Based on risk factors entered, Thrombocalc calculates a total risk score. Thrombocalc was designed to be prospectively completed after childbirth, before the woman left the location where delivery had occurred. The Hospital Thrombosis Committee elected to make individualized recommendations for pharmacological thromboprophylaxis based on each woman's total VTE risk score. Risk thresholds for initiating thromboprophylaxis were informed by previously published guidelines (5) . To incentivize Thrombocalc use and promote compliance with local thromboprophylaxis guidelines, clinicians received individualized recommendations for dosing and duration of pharmacological thromboprophylaxis in real time, following completion of the VTERA. These recommendations were accompanied by relevant warnings and contraindications to assist with the decision-making process. It was the responsibility of the attending clinician to make a final decision on whether to implement these recommendations. Mechanical thromboprophylaxis was recommended in line with existing local guidelines. After completing the electronic form, a paper copy of the risk assessment was printed and placed in each assessed woman's paper medical record. A worked example is shown in Figure 1 . Our institutional guidelines stipulate that women with specific VTE risk factors which place them at high risk of VTE (for example: inherited or acquired thrombophilia) are referred antenatally to the Specialist Thrombosis Clinic of the hospital. For these women, the care plan written antenatally by the attending hematologist supersedes Thrombocalc recommendations. Selecting these risk factors in the risk assessment tool referred end-users to the hematology care plan for patient-specific recommendations.
Thrombocalc implementation occurred in three phases. Phase 1 was a pilot and technical validation phase which assessed user acceptability and ensured that calculations within the clinical decision support system were functioning accurately (July-August 2014). Phase 2 (September 2014-mid-December 2014) encompassed the initial implementation of Thrombocalc into clinical areas. The electronic risk assessment tool was made available on desktop computers in the Delivery Suite and in the Operating Room. During this phase, thromboprophylaxis recommendations were masked while further technical validation of calculations was carried out. Phase 3 (midDecember 2014 to mid-December 2015) saw full implementation of Thrombocalc, and unmasking of thromboprophylaxis recommendations.
A number of strategies were employed to encourage compliance with VTERA throughout the implementation process. First and foremost, a user-centered approach was taken during the development. End-users were familiarized with the tool before implementation through an informal education campaign, including training sessions and circulation of internal memos and information documents. During the initial stages, members of the Thrombocalc team were present to assist staff and answer any questions. Regular communication and feedback to endusers encouraged compliance with VTERA. In addition, benefits to the patient and to staff workflow were highlighted to provide positive reinforcement.
When a Thrombocalc risk assessment form was completed, data entered were automatically collected and stored within the hospital network as individual files. These data were used to prospectively assess implementation and uptake of the electronic VTERA tool within the hospital. To create a working dataset, data were extracted from individual Thrombocalc risk assessments, collated and linked with records of all hospital deliveries. Data were imported into SPSS statistical software Version 22 (IBM Corp., Armonk, NY, USA) for analysis. All Thrombocalc assessments completed during the study period were eligible for inclusion. There were no exclusion criteria in this study; however, completed risk assessments were excluded from further analysis if insufficient information was available to allow patient identification. In the case of duplicate risk assessment forms, only the most recent Thrombocalc assessment was included.
Using the working dataset, we measured the proportion of women who gave birth in the hospital and had a Thrombocalc risk assessment completed after delivery. Trends in risk assessment were analyzed using descriptive statistics and Poisson regression. Univariable and multivariable regression analyses were used to assess determinants of Thrombocalc form completion.
Results
During the study period, 10 721 women delivered in the Rotunda Hospital, Dublin, Ireland. A total of 8525 Thrombocalc VTE risk assessment forms were completed. Of these, 145 were excluded due to either duplication (n = 135) or insufficient identification information (n = 10). The remaining 8380 VTE risk assessments were included in the final analysis, representing 78.2% of all women who gave birth in the study period.
End-users reported that Thrombocalc was easy to use and integrated with existing clinical workflows. End-users informally reported that risk assessment using Thrombocalc took less than one minute to complete. Thrombocalc risk assessment increased significantly over time from Table 1 details the weekly compliance rate at the end of each implementation phase. Poisson regression was used to calculate an incidence rate ratio of 1.04 [95% confidence interval (CI) 1.02-1.05, p < 0.001) for the first 3 months of full implementation (Phase 3). This indicates that the percentage change in the incidence rate of uptake was 4% per week during this 3-month period. Compliance remained consistent throughout the last 6 months of data collection. Fluctuation in uptake within this period can be described as random variation (incidence rate ratio 1, 95% CI 0.993-1.005, p = 0.798). In the last quarter of 2015, Thrombocalc VTERA forms were completed in over 92% of women who delivered in our institution. During the final week of data collection, 97% of women had Thrombocalc forms completed.
There was a small but statistically significant increase in completion of Thrombocalc risk assessment for deliveries that took place outside of normal working hours (between 20.00 and 08.00 hours) [odds ratio (OR) 1.14, 95% CI 1.04-1.25] (Table 2 ). However, this association did not persist when adjusted for other factors affecting delivery (delivery method and outcome) using multivariable logistic regression analysis [adjusted odds ratio (aOR) 1.03, 95% CI 0.93-1.14]. Thrombocalc completion was half as likely following a stillbirth delivery than following a live birth (OR 0.53, 95% CI 0.32-0.88). Similarly, Thrombocalc completion was less likely in those with cesarean deliveries than vaginal deliveries (OR 0.67, 95% CI 0.60-0.72). Both associations remained statistically significant when adjusted for confounding factors (namely, day and time of delivery, delivery outcome and delivery method) in a multivariable analysis (aOR 0.48, 95% CI 0.29-0.79 and aOR 0.66, 95% CI 0.60-0.73, respectively).
To assess the accuracy of completed Thrombocalc forms, a subset of information entered into the electronic tool was verified using an independent hospital database. Overall, 1234 incidences of information variance and risk factor misclassification were identified (Table 3) . Of the 8380 forms included for analysis, almost 14% (n = 1146) contained potentially inaccurate information, with a number of risk assessments (n = 88) containing more than one misclassification. Variances were noted in classification of age, parity, delivery outcome (live birth vs. stillbirth), gestational age and delivery method (cesarean delivery vs. vaginal delivery). In certain categories, we added a "borderline" misclassification. This was assessed after verification identified that the misclassification related to age, gestation or parity, and was within one unit of the correct figure. It is possible that the variance was due to rounding up or down by the end-user who entered the data when completing the risk assessment. For example: classing the woman as age ≥35 years when she was 34, 35 or 36 years, and parity ≥3 when there was ambiguity around whether the parity included or excluded the current delivery.
In 207 cases (2.5% of all Thrombocalc assessments completed), misclassification of risk factors resulted in potentially inaccurate thromboprophylaxis recommendations. These recommendations resulted in under-recommendation of thromboprophylaxis in 145 cases, and over-recommendation in 62 cases.
Discussion
Our VTERA tool, Thrombocalc, is a user-friendly electronic VTE risk assessment tool which is suitable for use in a busy obstetric environment. In our institution, Thrombocalc was successfully implemented, leading to a sustained increase in postpartum VTERA, achieving a median compliance of over 92% in the final quarter of data collection. Furthermore, this level of performance has been maintained after study completion.
Our study represents the largest formal implementation of an electronic score-based VTERA tool reported in an obstetric setting. Although several other score-based and IT-supported VTERA tools are reported in the obstetric literature (5, (7) (8) 13, (18) (19) (20) 29, 30) , the feasibility and practicalities of fully implementing these in a busy clinical environment is unreported. The high rates of VTERA achieved in our study demonstrate that individualized VTERA can be integrated into routine clinical practice and high rates of VTERA can be consistently achieved. Use of a readily available computer program offers an opportunity for similar electronic tools to be created or adjusted for local settings.
This study expands existing evidence demonstrating improved risk assessment rates and consistency in the identification of women at risk of pregnancy-associated VTE following implementation of a risk score (30) . Automatic calculation of a total risk score and recommendation of risk-appropriate thromboprophylaxis also offers an opportunity for streamlined assessment of VTE risk and implementation of local guidelines. Evidence from non-obstetric settings also indicates that computerbased risk assessment and clinical decision support tools increase adherence to guidelines and improve adequacy of thromboprophylaxis practices (21, 22) . Although better adherence to local thromboprophylaxis guidelines is reported by care providers in our institution, the absence of local data to corroborate this is noted as a limitation of our study. It should be noted that Thrombocalc is not currently integrated into an electronic health record (EHR); Thrombocalc is an independent electronic program. During the study period, completed Thrombocalc VTERAs were printed and placed in each woman's individual paper health records, which were the standard in our institution. Consequently, the high rates of compliance observed are independent of "hard stop" workflows, which mandate completion of VTERA before progressing with EHR tasks. Integration of electronic risk assessment into a predominantly paper-based workflow further demonstrates Thrombocalc's ease of use and high user-acceptability.
We aim to make Thrombocalc available for implementation through a national EHR for maternal and newborn care that is currently being implemented in all Irish maternity units on a phased basis. Integration of Thrombocalc into this EHR would further streamline the VTE risk assessment process, thereby reducing the burden on frontline staff, and will ensure accuracy of information entered.
The electronic format of Thrombocalc has standardized the process of risk assessment, but it is possible that some inaccurate risk assessments occurred due to incorrect information or incorrect form completion. Overall, we identified misclassification of VTE risk in a small proportion of our population (2.5%). Thrombocalc forms were completed by the midwife attending the delivery and the final decision regarding prescription of thromboprophylaxis was with the physician, therefore providing an opportunity for identification of such misclassification. Thrombocalc was not devised to replace clinical judgment but to aid the prescriber in comprehensive VTERA. We also identified clinical situations where VTERA was less likely to occur, namely, following cases of stillbirth and cesarean deliveries. Lower compliance with VTERA following stillbirth delivery may reflect the circumstances of the immediate postpartum period. We hypothesize that lower compliance with VTERA following cesarean deliveries may be due to a lower perceived importance of formal VTERA on the background of established local guidelines recommending postpartum thromboprophylaxis in all women undergoing cesarean section (31) . Consistent and comprehensive VTERA should be undertaken in all women, regardless of the clinical circumstances or perceived level of risk. Further quality improvement initiatives are ongoing to ensure VTERA is completed in all women who give birth in our institution, regardless of the mode of delivery or delivery outcome, and that all VTERAs are accurate at the time of completion.
The ultimate aim of VTERA and thromboprophylaxis is to reduce the incidence of VTE, a potentially fatal or disabling pregnancy complication. To assess the clinical impact of an electronic score-based VTERA such as Thrombocalc, data on maternal outcomes and the incidence of VTE within the population are required. However, due to the low incidence of VTE in the postnatal population (estimated to be 0.6 per 1000) (32) , clinical validation of such a risk assessment tool requires a large sample population. Further work is underway by our group as part of a larger body of research, progressing towards ascertainment of maternal outcomes in our population and validation of this electronic VTERA tool. In the absence of effectiveness data, assessing the impact of improved VTERA on adverse events, such as bleeding, has been identified as a priority. The risks and potential complications associated with VTERA and thromboprophylaxis using low molecular weight heparin will also be assessed as part of this research.
Even though significant differences exist in prophylaxis recommendations between the major guidelines (5,6), all guidelines are unanimous in their recommendation for repeated and documented assessment of VTE risk. Against these recommendations, compliance with VTERA postpartum is very poor in many institutions, at a time when a mother's VTE risk is highest. Until we have further evidence to harmonize practice, we need to perform VTERA on all women, regardless of mode of delivery and regardless of guidelines that are chosen in different institutions.
Our study provides new evidence demonstrating standardized assessment of VTE risk in individual postpartum women is possible, and sustainable, in a highthroughout, resource limited environment. Our findings provide evidence to support the use of electronic, scorebased VTE risk assessment; an approach which is proposed in the literature, yet previously unreported at this scale. Achieving such high rates of risk assessment assists in the identification of women who are at risk of pregnancy-associated VTE and, we hypothesize, promotes adherence to local guidelines, improves adequacy of thromboprophylaxis practices and potentially prevents avoidable maternal deaths from thrombosis and thromboembolism. Future work will evaluate the impact of excellent compliance with VTERA on our mothers' risk of postnatal VTE.
